Articles tagged with Chemotherapy
A new study found that a 21-gene test can identify patients with early breast cancer who can be spared chemotherapy and still survive five years after diagnosis. The trial showed a 94% disease-free survival rate among low-risk patients treated with hormone therapy alone.
A new study from the University of Texas M. D. Anderson Cancer Center found that neurofeedback significantly reduces chronic pain and improves quality of life in cancer patients with chemotherapy-induced neuropathy. The treatment, which uses electroencephalogram biofeedback to modify brain activity, showed a 73% improvement rate in pai...
Researchers at Rice University have developed a new method for synthesizing the potent anti-cancer agent trioxacarcin, which damages DNA and disrupts cancer cell replication. This breakthrough allows for more efficient production of these valuable molecules, enabling their study as potential new medications.
A clinical trial found that approximately a quarter of women with HER2 positive breast cancer who received combination treatment experienced significant tumor shrinkage or disappearance within 11 days. This discovery offers the possibility of tailoring treatment for each woman, potentially reducing the need for chemotherapy.
A new study found that low expression of SMARCA4/BRG1 gene in lung tumors may indicate patients who will benefit from certain chemotherapy regimens. The findings suggest an alternative therapy for these patients to spare them from cisplatin's side effects and allow them to try a different treatment sooner.
Researchers found that dose-dense adjuvant chemotherapy significantly improved overall survival after ten years by nearly a third compared to standard interval regimens. Dose-dense chemotherapy was not associated with an increased risk of treatment-induced amenorrhea, and it seemed effective irrespective of hormone receptor status.
Nanoparticulate drug carriers show promise in targeted cancer therapy, increasing therapeutic concentrations at tumor sites while minimizing harm to healthy tissues. This approach has the potential to improve treatment efficacy and reduce systemic toxicity.
Researchers identified 12 classes of drugs and 4 main mechanisms that can cause small arteries to constrict in response to cold, limiting blood supply. A recent study published in British Journal of Clinical Pharmacology highlights the need for further investigation into this condition.
Researchers at St. Joseph's Hospital and Medical Center found that a standard front-line treatment for advanced ovarian cancer should involve every three week chemotherapy with carboplatin, paclitaxel plus bevacizumab, or weekly dose intense paclitaxel without bevacizumab
Researchers have found that laser ablation creates a temporary opening in the blood-brain barrier, allowing chemotherapy drugs to pass into the brain. This breakthrough raises hopes for longer treatment options and improved patient outcomes.
Using laser probe, neurosurgeons deliver chemotherapy drugs to patients with glioblastoma after opening the blood-brain barrier. The technology allows for longer treatment windows and potentially limits harmful effects of chemotherapy.
Researchers develop adaptive therapy that adjusts drug dose based on tumor response, controlling growth and allowing 60-80% of mice to be weaned off the drug. The treatment approach stabilizes tumors by maintaining a small population of drug-sensitive cells to suppress resistant cell growth.
Researchers at MDI Biological Laboratory have discovered two drugs that could reverse peripheral nerve damage caused by chemotherapy, with applications also for diabetes and traumatic injuries. The drugs reduce MMP-13 activity, preventing degeneration of axons and restoring touch response in zebrafish.
A large-scale analysis of patient records found that chemotherapy before radiation therapy did not improve overall survival rates for head and neck cancer patients. Patients who received concurrent chemotherapy and radiation had slightly longer median overall survival times compared to those receiving chemotherapy alone.
Researchers from Case Western Reserve University have developed a new image analytics test that can reliably distinguish between patients who need only hormonal treatment and those who also need chemotherapy. The test uses MRI data to identify molecular changes in tissues, which can be analyzed quickly and cost-effectively.
A new study suggests that patients with resectable pancreatic cancer should receive at least 6 months of adjuvant chemotherapy to reduce distant disease recurrences and improve overall survival. Chemotherapy, but not chemoradiotherapy, significantly reduces the incidence of distant recurrence.
A recent clinical study found that ONC201 caused cell death in various tumor types, even when the p53 protein was mutated or deleted. The drug has shown promise in treating hematological malignancies, including leukemia and lymphoma patients, with clinical trials recently initiated.
Researchers from Massachusetts General Hospital report that inducing cytotoxic T cell infiltration into lung tumors can make them sensitive to checkpoint blockade. Combining chemotherapy with immune checkpoint therapies achieves long-lasting control of tumor growth in animal models, expanding the potential for effective treatment.
Researchers found that pediatric ALL patients treated with chemotherapy alone remain at risk for attention and learning problems, even after treatment ends. The study, published in the Journal of Clinical Oncology, suggests that early intervention is crucial to prevent academic difficulties.
A new study from Children's Hospital Los Angeles found that leukemia therapy leads to a significant drop in bone mineral density during the first month of treatment, affecting the lower spine and legs. This earlier onset than previously thought highlights the need for new approaches to mitigate bone toxicity in cancer patients.
Researchers at Rockefeller University have captured atomic images of the herpes simplex 1 virus revealing how it inserts itself into another protein to evade detection by immune cells. The study provides a mechanistic explanation for the virus's ability to escape immune system recognition.
A portable method to detect tainted medicines and supplements has been developed by a CWRU researcher, potentially improving public health globally. The device uses Nuclear Quadrupole Resonance spectroscopy to authenticate good medicines and supplements, while also addressing the issue of counterfeit products.
A study by University of Minnesota researchers identified the mechanism of 5-azacytidine, a DNA-based drug that blocks HIV's ability to spread. The drug converts to a DNA form and infiltrates HIV when it turns RNA into DNA, stopping replication.
Experts have issued a framework to guide difficult prioritization decisions among children in need of scarce life-saving chemotherapy treatment. The modified utilitarian model maximizes total benefit from available supply, considering factors like curability, prognosis, and drug importance.
Microtubules can spontaneously form large networks through the interaction of motor proteins. This self-organization is crucial for cell division and may inspire new materials and drug designs. Researchers developed a model describing this behavior, which could lead to breakthroughs in biology and material science.
A three-year study funded by PCORI investigates the safety and patient preferences of discharge strategies after chemotherapy for children with acute myeloid leukemia. The study aims to gather data on bloodstream infections and chemotherapy delays to inform better care for these vulnerable patients.
Chemotherapy can reduce the body's immune response, leaving breast cancer survivors vulnerable to illnesses. Researchers found that levels of lymphocytes and antibodies dropped significantly after chemotherapy, with only partial recovery in some cases.
Researchers have identified a biomarker, CDX2, that can predict which Stage II colon cancer patients are most likely to benefit from chemotherapy after surgery. The study found that patients without CDX2 had poorer outcomes, but those treated with chemotherapy had improved survival rates.
A new treatment model recommends aggressive surgery followed by targeted chemotherapy to achieve a 50% cure rate for women with advanced-stage ovarian cancer. This approach differs from current conventional treatments, which often result in a 20% survival rate.
A new biomarker, CDX2, has been identified that predicts which stage II colon cancer patients may benefit from chemotherapy. The study found that tumors lacking CDX2 expression were more likely to benefit from adjuvant chemotherapy than those with CDX2 expression.
Researchers have discovered a way to light up a common cancer drug, allowing them to see where the chemo goes and how long it takes to get there. This breakthrough could lead to more personalized medicine and better understanding of how cells interact with drugs.
Researchers developed a device that produces tiny capsules with multiple inner ingredients, which can be triggered to mix and release toxic product only near the tumor site. The method has shown promise for increasing drug efficiency while reducing side effects in cancer treatment.
Researchers from the Repurposing Drugs in Oncology project have found that diclofenac, a common painkiller, has significant anti-cancer properties. The study suggests that existing non-cancer drugs may represent a valuable source of novel therapies for cancer treatment.
Scientists have developed a new strategy for constructing highly specific synthetic pores using DNA, which can control the release of therapeutics. The pores are designed to act like doors, opening only when provided with the right key, allowing for precise targeting of drugs to specific tissues.
A new study reveals that docetaxel retains effectiveness in patients with castration-resistant metastatic prostate cancer (mCRPC) treated with abiraterone. Following abiraterone, 40% of patients experienced a 50% reduction in prostate-specific antigen (PSA), demonstrating the activity of this drug sequencing.
A study by CNIC researchers has identified a new mechanism through which blood stem cells regulate their proliferation and microenvironment. The protein ESL-1 controls the production of TGF-, a cytokine with antiproliferative properties, and is essential for maintaining HSCs in diseases like anemia.
Researchers from Colorado State University have discovered that RNA plays a crucial role in DNA damage, leading to mutations and disease. The study sheds light on the mechanisms behind Aicardi-Goutieres syndrome and has implications for cancer research.
A study found that women with breast cancer who received chemotherapy and triptorelin had a higher long-term probability of ovarian function recovery without affecting pregnancy rates or disease-free survival. The treatment showed modest benefits regarding potential prevention of treatment-associated infertility.
Researchers have developed models to rationalize the action of chemotherapeutic molecules on body cells, enabling better understanding of how drugs interact with biological targets. The study aims to improve the design of new therapeutic molecules, resulting in more effective and side-effect-free drugs.
The LUX-Lung 7 trial shows afatinib significantly improved progression-free survival, time-to-treatment failure and objective response rate compared to gefitinib. Afatinib is considered the EGFR tyrosine kinase inhibitor of choice for first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer.
Researchers discovered that aggressive tumors hijack an export pathway in cells to lay the groundwork for cancer progression and resistance to chemotherapy. Blocking this pathway may help restore tumor vulnerability to chemotherapy.
Researchers found that combining TTFields with chemotherapy significantly improved progression-free and overall survival for patients with glioblastoma. The study, published in JAMA, suggests a potential new treatment approach for this devastating brain tumor.
A recent study published in Endocrinology Today holds promise for cancer patients undergoing chemotherapy to protect their fertility and defense systems. Researchers found that the potent humanin analogue (HNG) protected male germ cells and white blood cells, reducing infertility and infection susceptibility.
Studies found that patients with delayed breast cancer surgery and chemotherapy had poorer overall and disease-specific survival rates. A delay of up to 90 days in receiving chemotherapy was associated with no adverse outcomes, but prolonged delays led to increased risks of death from the disease.
A new study from MD Anderson Cancer Center found that delaying chemotherapy after surgery increases the risk of death for breast cancer patients, particularly those with triple-negative breast cancer. Patients who start treatment within 90 days have a lower risk of death compared to those who delay it.
A phase III trial found that women with luminal A subtype of breast cancer had comparable 10-year disease-free survival rates regardless of whether or not they received adjuvant chemotherapy. In contrast, patients with non-luminal A subtypes who received chemotherapy were 50% less likely to have their disease recur in 10 years.
Adding carboplatin to presurgery chemotherapy significantly improved disease-free survival rates for patients with triple-negative breast cancer (TNBC). The study found that patients with pathologic complete responses had the lowest risk of relapse, supporting the use of carboplatin as a standard part of neoadjuvant therapy regimens.
A phase III trial found that capecitabine improved disease-free survival for women with HER2-negative breast cancer that was not eliminated by presurgery chemotherapy. The study showed a 30% reduced risk of disease recurrence compared to standard therapy.
Midostaurin has been shown to improve the five-year survival rate of patients with high-risk acute myeloid leukemia (AML) who carry the FLT-3 gene mutation. The clinical trial found that midostaurin added to standard chemotherapy reduced the risk of death by 23% compared to placebo, resulting in a 50.9% five-year survival rate.
A clinical trial showed midostaurin, a multi-kinase inhibitor, improved the five-year survival rate of patients with high-risk acute myeloid leukemia (AML) who carry the FLT-3 gene mutation. The treatment resulted in a 50.9% survival rate compared to 43.9% for those without the mutation.
A recent study published in the New England Journal of Medicine found that ibrutinib, a targeted drug, was superior to chlorambucil in treating chronic lymphocytic leukemia (CLL) patients. The study showed improved progression-free survival, overall response rate, and overall survival rates for patients taking ibrutinib.
UC Davis researchers have made significant progress in tumor treatment by combining guided ultrasound with nanoparticle chemotherapy, resulting in improved survival and consistent cure rates. The technique allows for complete destruction of tumors without thermal damage to surrounding tissue.
Breast cancer patients treated with anthracycline-based chemotherapy experienced lower verbal memory and default mode brain network connectivity compared to non-chemotherapy groups. Cognitive dysfunction was also elevated in both treatment groups, highlighting the need for further research into chemotherapy-related neurotoxic effects.
Researchers at National Research Tomsk State University found that neoadjuvant chemotherapy can stimulate evolution of the tumor, leading to resistance and metastasis. The study analyzed biopsies from women with breast cancer before and after surgery, revealing a 23% increase in new tumor formation.
A recent Yale University study found that black women with stage I-III cancer are less responsive to neoadjuvant chemotherapy compared to other racial groups. Despite presenting with more advanced-stage and aggressive tumors, the findings suggest biologic differences or disparities in treatment may be contributing factors.
The International Society of Neurogastronomy Symposium brought together scientists, chefs, and patients to explore ways to improve quality of life for those with altered taste or smell. Chefs and neuroscientists collaborated on the 'Applied Neurogastronomy Challenge' to create dishes that appealed to cancer patients.
Researchers at Brigham Young University create a system to speed up vaccine production by storing the biological machinery in a freeze-dried state. This allows labs to rapidly produce vaccines with just the addition of water, reducing the time from months to days.
A new study published in JAMA-Oncology found that a personalized approach to treating chemotherapy-induced nausea and vomiting is more effective than the existing 'one size fits all' guidelines. Patients at higher risk of nausea and vomiting due to personal factors such as age, pregnancy history, or travel sickness showed significant i...
A study at MD Anderson Cancer Center found that suppressing epithelial-to-mesenchymal transition (EMT) in combination with gemcitabine may boost the drug's effectiveness against pancreatic cancer. EMT suppression leads to impaired sensitivity to chemotherapy, causing poor prognosis and metastasis.
A study published in PLOS ONE found that a small dose of dexrazoxane protected ovarian function and fertility in mice after chemotherapy. The treatment also increased survival rates and reduced toxicity, providing new hope for young cancer patients.